Future Therapeutic Strategies for Alzheimer's Disease: Focus on Behavioral and Psychological Symptoms
Alzheimer's disease (AD) is a progressive, degenerative brain disorder that impairs memory and thinking skills, leading to significant economic and humanistic burdens. It is associated with various neuropsychiatric symptoms (NPS) such as anxiety, agitation, depression, aggression, apathy, and p...
Gespeichert in:
Veröffentlicht in: | International journal of molecular sciences 2024-11, Vol.25 (21), p.11338 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 21 |
container_start_page | 11338 |
container_title | International journal of molecular sciences |
container_volume | 25 |
creator | Kwon, Kyoung Ja Kim, Hahn Young Han, Seol-Heui Shin, Chan Young |
description | Alzheimer's disease (AD) is a progressive, degenerative brain disorder that impairs memory and thinking skills, leading to significant economic and humanistic burdens. It is associated with various neuropsychiatric symptoms (NPS) such as anxiety, agitation, depression, aggression, apathy, and psychosis. NPSs are common in patients with AD, affecting up to 97% of individuals diagnosed with AD. The severity of NPS is linked to disease progression and cognitive decline. NPS in Alzheimer's disease leads to increased morbidity, mortality, caregiver burden, earlier nursing home placement, and higher healthcare costs. Despite their significant impact, clinical research on NPS in AD is limited. In clinical settings, accurately distinguishing and diagnosing NPS related to AD remains a challenge. Additionally, conventional treatments for NPS in AD are often ineffective, highlighting the need for new therapies that target these specific symptoms. Understanding these comorbidities can aid in early diagnosis and better management of AD. In this review, we provide a summary of the various neurological and psychiatric symptoms (NPS) associated with AD and new candidates under development for the treatment of NPS based on their therapeutic targets and mechanisms. On top of the conventional NPS studied so far, this review adds recent advancements in the understanding of social functional impairment in AD. This review also provides information that can contribute to the advancement of studies and translational research in this field by emphasizing therapeutic targets and mechanisms of action focused on AD-related NPS rather than conventional mechanisms targeted in AD drug development. Above all, considering the relative lack of research in this new field despite the importance of clinical, medical, and translational research, it may increase interest in NPS in AD, its pathophysiological mechanisms, and potential therapeutic candidates such as molecules with antioxidant potential. |
doi_str_mv | 10.3390/ijms252111338 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11547068</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A815345751</galeid><sourcerecordid>A815345751</sourcerecordid><originalsourceid>FETCH-LOGICAL-c369t-d4d3d3a31b4ea83a06e69bdc8d17660f7b83ccac45ce8648e10206aab76d21be3</originalsourceid><addsrcrecordid>eNptkktv1DAUhS0EoqWwZIsssYBNWj9ix2GDhtIplSqB1LK2HPtm4lEST-2k0vDr8ajPQdgLX11_91jHOgi9p-SY85qc-PWQmGCUUs7VC3RIS8YKQmT18ll9gN6ktCaEcSbq1-iA14IqVbNDBMt5miPg6w6i2cA8eYuvpmgmWHlIuA0RL_o_HfgB4qeEv_sEJsEXvAx2TjiM-Bt05taHaHpsRod_pa3tQh9W3ubO1XbYTGFIb9Gr1vQJ3t2fR-j38uz69Edx-fP84nRxWVgu66lwpeOOG06bEozihkiQdeOscrSSkrRVo7i1xpbCgpKlAkoYkcY0lXSMNsCP0Nc73c3cDOAsjNlKrzfRDyZudTBe79-MvtOrcKspFWVFpMoKn-8VYriZIU168MlC35sRwpw0p0xVZV40ox__QddhjmP2t6MkEZxU_IlamR60H9uQH7Y7Ub1QVPBSVGKndfwfKm8Hg7dhhNbn_t5AcTdgY0gpQvtokhK9C4beC0bmPzz_mUf6IQn8L6TztFg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3126053073</pqid></control><display><type>article</type><title>Future Therapeutic Strategies for Alzheimer's Disease: Focus on Behavioral and Psychological Symptoms</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Kwon, Kyoung Ja ; Kim, Hahn Young ; Han, Seol-Heui ; Shin, Chan Young</creator><creatorcontrib>Kwon, Kyoung Ja ; Kim, Hahn Young ; Han, Seol-Heui ; Shin, Chan Young</creatorcontrib><description>Alzheimer's disease (AD) is a progressive, degenerative brain disorder that impairs memory and thinking skills, leading to significant economic and humanistic burdens. It is associated with various neuropsychiatric symptoms (NPS) such as anxiety, agitation, depression, aggression, apathy, and psychosis. NPSs are common in patients with AD, affecting up to 97% of individuals diagnosed with AD. The severity of NPS is linked to disease progression and cognitive decline. NPS in Alzheimer's disease leads to increased morbidity, mortality, caregiver burden, earlier nursing home placement, and higher healthcare costs. Despite their significant impact, clinical research on NPS in AD is limited. In clinical settings, accurately distinguishing and diagnosing NPS related to AD remains a challenge. Additionally, conventional treatments for NPS in AD are often ineffective, highlighting the need for new therapies that target these specific symptoms. Understanding these comorbidities can aid in early diagnosis and better management of AD. In this review, we provide a summary of the various neurological and psychiatric symptoms (NPS) associated with AD and new candidates under development for the treatment of NPS based on their therapeutic targets and mechanisms. On top of the conventional NPS studied so far, this review adds recent advancements in the understanding of social functional impairment in AD. This review also provides information that can contribute to the advancement of studies and translational research in this field by emphasizing therapeutic targets and mechanisms of action focused on AD-related NPS rather than conventional mechanisms targeted in AD drug development. Above all, considering the relative lack of research in this new field despite the importance of clinical, medical, and translational research, it may increase interest in NPS in AD, its pathophysiological mechanisms, and potential therapeutic candidates such as molecules with antioxidant potential.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms252111338</identifier><identifier>PMID: 39518892</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Alzheimer Disease - diagnosis ; Alzheimer Disease - psychology ; Alzheimer Disease - therapy ; Alzheimer's disease ; Animals ; Anxiety ; Apathy ; Behavior ; Brain ; Caregivers ; Causes of ; Clinical trials ; Cognitive ability ; Complications and side effects ; Dementia ; Disease ; Drug therapy ; Hallucinations ; Humans ; Hypertension ; Mental depression ; Older people ; Psychological manifestations of general diseases ; Psychosis ; Quality of life ; Review ; Serotonin ; Side effects</subject><ispartof>International journal of molecular sciences, 2024-11, Vol.25 (21), p.11338</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 by the authors. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c369t-d4d3d3a31b4ea83a06e69bdc8d17660f7b83ccac45ce8648e10206aab76d21be3</cites><orcidid>0000-0001-9591-4005 ; 0000-0003-3608-2514 ; 0000-0003-4631-7073</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11547068/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11547068/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39518892$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kwon, Kyoung Ja</creatorcontrib><creatorcontrib>Kim, Hahn Young</creatorcontrib><creatorcontrib>Han, Seol-Heui</creatorcontrib><creatorcontrib>Shin, Chan Young</creatorcontrib><title>Future Therapeutic Strategies for Alzheimer's Disease: Focus on Behavioral and Psychological Symptoms</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Alzheimer's disease (AD) is a progressive, degenerative brain disorder that impairs memory and thinking skills, leading to significant economic and humanistic burdens. It is associated with various neuropsychiatric symptoms (NPS) such as anxiety, agitation, depression, aggression, apathy, and psychosis. NPSs are common in patients with AD, affecting up to 97% of individuals diagnosed with AD. The severity of NPS is linked to disease progression and cognitive decline. NPS in Alzheimer's disease leads to increased morbidity, mortality, caregiver burden, earlier nursing home placement, and higher healthcare costs. Despite their significant impact, clinical research on NPS in AD is limited. In clinical settings, accurately distinguishing and diagnosing NPS related to AD remains a challenge. Additionally, conventional treatments for NPS in AD are often ineffective, highlighting the need for new therapies that target these specific symptoms. Understanding these comorbidities can aid in early diagnosis and better management of AD. In this review, we provide a summary of the various neurological and psychiatric symptoms (NPS) associated with AD and new candidates under development for the treatment of NPS based on their therapeutic targets and mechanisms. On top of the conventional NPS studied so far, this review adds recent advancements in the understanding of social functional impairment in AD. This review also provides information that can contribute to the advancement of studies and translational research in this field by emphasizing therapeutic targets and mechanisms of action focused on AD-related NPS rather than conventional mechanisms targeted in AD drug development. Above all, considering the relative lack of research in this new field despite the importance of clinical, medical, and translational research, it may increase interest in NPS in AD, its pathophysiological mechanisms, and potential therapeutic candidates such as molecules with antioxidant potential.</description><subject>Alzheimer Disease - diagnosis</subject><subject>Alzheimer Disease - psychology</subject><subject>Alzheimer Disease - therapy</subject><subject>Alzheimer's disease</subject><subject>Animals</subject><subject>Anxiety</subject><subject>Apathy</subject><subject>Behavior</subject><subject>Brain</subject><subject>Caregivers</subject><subject>Causes of</subject><subject>Clinical trials</subject><subject>Cognitive ability</subject><subject>Complications and side effects</subject><subject>Dementia</subject><subject>Disease</subject><subject>Drug therapy</subject><subject>Hallucinations</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Mental depression</subject><subject>Older people</subject><subject>Psychological manifestations of general diseases</subject><subject>Psychosis</subject><subject>Quality of life</subject><subject>Review</subject><subject>Serotonin</subject><subject>Side effects</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkktv1DAUhS0EoqWwZIsssYBNWj9ix2GDhtIplSqB1LK2HPtm4lEST-2k0vDr8ajPQdgLX11_91jHOgi9p-SY85qc-PWQmGCUUs7VC3RIS8YKQmT18ll9gN6ktCaEcSbq1-iA14IqVbNDBMt5miPg6w6i2cA8eYuvpmgmWHlIuA0RL_o_HfgB4qeEv_sEJsEXvAx2TjiM-Bt05taHaHpsRod_pa3tQh9W3ubO1XbYTGFIb9Gr1vQJ3t2fR-j38uz69Edx-fP84nRxWVgu66lwpeOOG06bEozihkiQdeOscrSSkrRVo7i1xpbCgpKlAkoYkcY0lXSMNsCP0Nc73c3cDOAsjNlKrzfRDyZudTBe79-MvtOrcKspFWVFpMoKn-8VYriZIU168MlC35sRwpw0p0xVZV40ox__QddhjmP2t6MkEZxU_IlamR60H9uQH7Y7Ub1QVPBSVGKndfwfKm8Hg7dhhNbn_t5AcTdgY0gpQvtokhK9C4beC0bmPzz_mUf6IQn8L6TztFg</recordid><startdate>20241101</startdate><enddate>20241101</enddate><creator>Kwon, Kyoung Ja</creator><creator>Kim, Hahn Young</creator><creator>Han, Seol-Heui</creator><creator>Shin, Chan Young</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9591-4005</orcidid><orcidid>https://orcid.org/0000-0003-3608-2514</orcidid><orcidid>https://orcid.org/0000-0003-4631-7073</orcidid></search><sort><creationdate>20241101</creationdate><title>Future Therapeutic Strategies for Alzheimer's Disease: Focus on Behavioral and Psychological Symptoms</title><author>Kwon, Kyoung Ja ; Kim, Hahn Young ; Han, Seol-Heui ; Shin, Chan Young</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c369t-d4d3d3a31b4ea83a06e69bdc8d17660f7b83ccac45ce8648e10206aab76d21be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Alzheimer Disease - diagnosis</topic><topic>Alzheimer Disease - psychology</topic><topic>Alzheimer Disease - therapy</topic><topic>Alzheimer's disease</topic><topic>Animals</topic><topic>Anxiety</topic><topic>Apathy</topic><topic>Behavior</topic><topic>Brain</topic><topic>Caregivers</topic><topic>Causes of</topic><topic>Clinical trials</topic><topic>Cognitive ability</topic><topic>Complications and side effects</topic><topic>Dementia</topic><topic>Disease</topic><topic>Drug therapy</topic><topic>Hallucinations</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Mental depression</topic><topic>Older people</topic><topic>Psychological manifestations of general diseases</topic><topic>Psychosis</topic><topic>Quality of life</topic><topic>Review</topic><topic>Serotonin</topic><topic>Side effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kwon, Kyoung Ja</creatorcontrib><creatorcontrib>Kim, Hahn Young</creatorcontrib><creatorcontrib>Han, Seol-Heui</creatorcontrib><creatorcontrib>Shin, Chan Young</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kwon, Kyoung Ja</au><au>Kim, Hahn Young</au><au>Han, Seol-Heui</au><au>Shin, Chan Young</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Future Therapeutic Strategies for Alzheimer's Disease: Focus on Behavioral and Psychological Symptoms</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2024-11-01</date><risdate>2024</risdate><volume>25</volume><issue>21</issue><spage>11338</spage><pages>11338-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Alzheimer's disease (AD) is a progressive, degenerative brain disorder that impairs memory and thinking skills, leading to significant economic and humanistic burdens. It is associated with various neuropsychiatric symptoms (NPS) such as anxiety, agitation, depression, aggression, apathy, and psychosis. NPSs are common in patients with AD, affecting up to 97% of individuals diagnosed with AD. The severity of NPS is linked to disease progression and cognitive decline. NPS in Alzheimer's disease leads to increased morbidity, mortality, caregiver burden, earlier nursing home placement, and higher healthcare costs. Despite their significant impact, clinical research on NPS in AD is limited. In clinical settings, accurately distinguishing and diagnosing NPS related to AD remains a challenge. Additionally, conventional treatments for NPS in AD are often ineffective, highlighting the need for new therapies that target these specific symptoms. Understanding these comorbidities can aid in early diagnosis and better management of AD. In this review, we provide a summary of the various neurological and psychiatric symptoms (NPS) associated with AD and new candidates under development for the treatment of NPS based on their therapeutic targets and mechanisms. On top of the conventional NPS studied so far, this review adds recent advancements in the understanding of social functional impairment in AD. This review also provides information that can contribute to the advancement of studies and translational research in this field by emphasizing therapeutic targets and mechanisms of action focused on AD-related NPS rather than conventional mechanisms targeted in AD drug development. Above all, considering the relative lack of research in this new field despite the importance of clinical, medical, and translational research, it may increase interest in NPS in AD, its pathophysiological mechanisms, and potential therapeutic candidates such as molecules with antioxidant potential.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>39518892</pmid><doi>10.3390/ijms252111338</doi><orcidid>https://orcid.org/0000-0001-9591-4005</orcidid><orcidid>https://orcid.org/0000-0003-3608-2514</orcidid><orcidid>https://orcid.org/0000-0003-4631-7073</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1422-0067 |
ispartof | International journal of molecular sciences, 2024-11, Vol.25 (21), p.11338 |
issn | 1422-0067 1661-6596 1422-0067 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11547068 |
source | MDPI - Multidisciplinary Digital Publishing Institute; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
subjects | Alzheimer Disease - diagnosis Alzheimer Disease - psychology Alzheimer Disease - therapy Alzheimer's disease Animals Anxiety Apathy Behavior Brain Caregivers Causes of Clinical trials Cognitive ability Complications and side effects Dementia Disease Drug therapy Hallucinations Humans Hypertension Mental depression Older people Psychological manifestations of general diseases Psychosis Quality of life Review Serotonin Side effects |
title | Future Therapeutic Strategies for Alzheimer's Disease: Focus on Behavioral and Psychological Symptoms |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T12%3A22%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Future%20Therapeutic%20Strategies%20for%20Alzheimer's%20Disease:%20Focus%20on%20Behavioral%20and%20Psychological%20Symptoms&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Kwon,%20Kyoung%20Ja&rft.date=2024-11-01&rft.volume=25&rft.issue=21&rft.spage=11338&rft.pages=11338-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms252111338&rft_dat=%3Cgale_pubme%3EA815345751%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3126053073&rft_id=info:pmid/39518892&rft_galeid=A815345751&rfr_iscdi=true |